NMDP

🚨 BREAKING: We’re one step closer to ensuring every patient has access to the life-saving transplant they need. https://lnkd.in/giaFKzVG

🚨 NEW research published in the Journal of Clinical Oncology❗ A national, multi-center study from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) found that patients with blood cancers and other blood diseases had no difference in transplant outcomes when physicians used a donor search prognosis strategy to guide donor selection. Key takeaways: ▪️ No difference in 2-year survival or other outcomes between patients very likely vs. very unlikely to find a matched unrelated donor (MUD) ▪️ Faster time to transplant when physicians pivoted quickly to alternative donors, which also delays disease progression These results overturn previously-established research that only fully matched donors provide the best outcomes—showing that the right donor is often the one who’s available now. ➡️ 🔗 Read the full study in JCO: https://lnkd.in/gHUQdnA5

With groundbreaking research through our collaborative program, CIBMTR, more patients diagnosed with a blood cancer or disorder can now receive their life-saving cell therapy.

For over 35 years, we’ve been at the forefront of research through our collaborative program, CIBMTR — with the goal of providing equal access to life-saving treatment for all patients suffering from a blood cancer or disorder.

The odds are changing. With NMDP-sponsored research through our collaborative program, CIBMTR, more patients diagnosed with a blood cancer or disorder can now receive a transplant — through a mismatched, unrelated donor.

Historically, ethnically diverse patients diagnosed with a blood cancer or disorder had less than a 50% chance of finding an unrelated transplant match. But with NMDP-sponsored research through our collaborative program, CIBMTR, those odds are changing.